Objective To estimate deployment of field medical equipment, which is aim at the manifold differences between field medical equipment in wartime or emergencies and common hospital equipment. Methods Based on a good many factors, the system of comprehensive evaluation index on field medical equipment deployment were built up. The model of comprehensive evaluation index was established in applicant of a grey system theory. By discriminating model parameters, the order of comprehensive evaluation is involved in various medical equipment deployments. Results The examples of the evaluation show that is simple and convenient, lesser relevance in indicators and the evaluative results and actual position are conformity. Conclusion The evaluated results of field medical equipment deployment are important for the selection of field medical equipment, which can meet all deployable conditions in wartime or various emergencies. At the same time, the theoretic method has also settled the foundation in evaluation of other military equipment deployment.

This paper introduced the application and effects of mobile operating room nursing information management system (MORNIMS) in the operating room. The MORNIMS was designed by operating room and information center based on the Enterprises Digital Assistant (EDA) and was applied in the operating room for two years. Its application significantly improved work efficiency,optimized the work flow,reduced nursing mistakes,enhanced the retrospective quality monitoring of sterile materials,and realized information management in the operating room.

OBJECTIVETo investigate the differential expression pattern of hsa-miR-9 between EBV-positive and -negative Burkitt lymphoma cell lines and its association with BCL-6.

METHODSThe expression of hsa-miR9 and BCL-6 mRNAs in EBV(+) Raji and EBV-Ramous cells in mRNA levels were detected using fluorescence quantitative PCR (QRT-PCR). The two cells lines were transiently transfected with hsa-mir9-inhibitor and hsa-mir9-minicsvia Oligofectamine 2000, and the changes in BCL6 expressions was detected using QRT-PCR and Western blotting. Annexin V/PI staining was used to analyze the apoptosis and morphological changes of the transfected cells.

RESULTSThe expression of Hsa-miR9 and BCL-6 was significantly higher in EBV(+) Raji cells than EBV(-) Ramous cells (P<0.01). BCL-6 mRNA and protein expression was reduced in EBV(+) Raji cells after transfection with hsa-miR9-inhibitor but up-regulated in EBV(-) Ramous cells transfected with hsa-miR9-minics. Flow cytometry revealed a significantly decreased apoptosis rate in EBV(+) Raji cells transfected with hsa-miR9-inhibitor but an increased rate in EBV(-) Ramous cells transfected with hsa-miR9-minics, and the results were confirmed by microscopic observations.

CONCLUSIONHsa-miR9 positively regulate the expression of BCL-6 and apoptosis of EBV(+) Raji cells and EBV(-) Ramous cells.

Apoptosis ; Burkitt Lymphoma ; genetics ; pathology ; virology ; Cell Division ; Cell Line, Tumor ; DNA-Binding Proteins ; genetics ; metabolism ; Gene Expression Regulation, Neoplastic ; Herpesvirus 4, Human ; Humans ; MicroRNAs ; metabolism ; Proto-Oncogene Proteins c-bcl-6 ; Transfection

The majority patients of differentiated thyroid carcinoma (DTC) with indolent progression have general good prognosis after standard primary treatments including surgery, thyroid stimulating hormone (TSH) suppression and radioactive iodine (RAI) therapy. However, there are still some patients suffered from recurrence or distant metastasis after initial treatment. They may lose the ability of uptaking iodine during their natural course of disease or treatment and could not benefit from subsequent RAI treatment, which will result in radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Options are very limited for RAIR-DTC patients, which is associated with a poor prognosis. Recently, with the research advances on the molecular mechanism of RAIR-DTC, redifferentiation combined with RAI therapy have been increasingly used to treat RAIR-DTC, and some outcomes are quite encouraging. This paper reviews the progress of signaling pathway inhibitors, histone deacetylase inhibitors, DNA methyltransferase inhibitors, retinoids and peroxisome proliferator-activated receptor agonists in redifferentiating therapy of RAIR-DTC.